In this episode of the NeuroOp Guru in collaboration with Ophthalmology Times, host Andrew G. Lee, MD, is joined by Drew Carey, MD, to discuss pretreatment features associated with vision improvement ...
An Australian study 1 reported that directional optical coherence tomography (OCT) images showed that Parkinson’s disease (PD) is associated with a thicker photoreceptor nuclear ...
The ongoing GARDian3 study is designed to assess whether a single subretinal administration of OCU410ST can slow structural ...
A study from 7 institutions in Hong Kong reported that tapering of low-dose atropine before the drug was discontinued had ...
A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
A phase 1b randomized, head-to-head study suggests that the investigational VEGF/Ang2 bispecific antibody OLN324 may offer ...
The University of Rochester’s Flaum Eye Institute is embedding behavioral health into ophthalmology to improve patient care ...
Major ophthalmic events in the first quarter of 2026 included treatments for presbyopia, age-related macular degeneration ...
Viridian Therapeutics issued a press release that announced the positive elegrobart topline results from the phase 3 REVEAL-1 ...
David A. DiLoreto Jr., MD, PhD, is chair of ophthalmology and director of the Flaum Eye Institute at the University of ...
ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...
Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results